Kevin Chinn, vice president and head of the cell & gene therapy service line at Cencora, outlines why early planning, ...

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, explains the meaning behind Scope 3 emissions, including why they ...